X4 Pharmaceuticals Inc (XFOR)
0.2743
-0.32
(-53.67%)
USD |
NASDAQ |
Nov 13, 16:00
0.2957
+0.02
(+7.80%)
After-Hours: 20:00
X4 Pharmaceuticals Debt to Equity Ratio: 0.7944 for June 30, 2024
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2024 | 0.7944 |
| March 31, 2024 | 52.92 |
| December 31, 2023 | 1.068 |
| September 30, 2023 | 0.8037 |
| June 30, 2023 | 0.4827 |
| March 31, 2023 | 0.6266 |
| December 31, 2022 | 0.454 |
| September 30, 2022 | 0.5393 |
| June 30, 2022 | 1.101 |
| Date | Value |
|---|---|
| March 31, 2022 | 0.6683 |
| December 31, 2021 | 0.5268 |
| September 30, 2021 | 0.4912 |
| June 30, 2021 | 0.376 |
| March 31, 2021 | 0.3119 |
| December 31, 2020 | 0.4557 |
| September 30, 2020 | 0.2847 |
| June 30, 2020 | 0.2422 |
| March 31, 2020 | 0.2127 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
0.2127
Minimum
Mar 2020
52.92
Maximum
Mar 2024
3.464
Average
0.509
Median
Debt to Equity Ratio Benchmarks
| NovaBay Pharmaceuticals Inc | -1.128 |
| Palatin Technologies Inc | 0.00 |
| iBio Inc | 0.0461 |
| Theriva Biologics Inc | -- |
| Oragenics Inc | -- |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 210.61M |
| Total Liabilities (Quarterly) | 116.16M |
| Shareholders Equity (Quarterly) | 94.45M |
| Current Ratio | 6.069 |
| Net Debt Paydown Yield | -8.74% |